Brendan Weiss, MD, of the University of Pennsylvania discusses the study he presented at the 58th Annual ASH Meeting & Exposition examining the safety and efficacy of NEOD001 in patients with AL Amyloidosis.

Reference
Gertz MA, Comenzo RL, Landau H, et al. NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study Presented at the 58th ASH Annual Meeting & Exposition; San Diego, CA: December 3-6, 2016. Abstract 644.

Liedtke M, Comenzo RL, Landau H, et al. Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response. Presented at the 58th ASH Annual Meeting & Exposition; San Diego, CA: December 3-6, 2016. Abstract 647.

свернуть